At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 39 enrolled
Drug / intervention
PF-04958242 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia
In Brief
A Phase 1 clinical trial evaluating PF-04958242 and Placebo for Schizophrenia. Completed, enrolled 39 participants across 1 site.
Detailed Summary
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionApr 2015
TodayJul 2026
First PostedJan 7, 2015
Enrollment StartJan 6, 2015
Primary CompletionApr 15, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.5 years ago
Interventions
PF-04958242drug
Administered as specified in the treatment arm
Placebodrug
Administered as specified in the treatment arm